These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 20547658)

  • 41. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
    Choy E; McKenna F; Vencovsky J; Valente R; Goel N; Vanlunen B; Davies O; Stahl HD; Alten R
    Rheumatology (Oxford); 2012 Jul; 51(7):1226-34. PubMed ID: 22344576
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.
    van der Heijde D; Keystone EC; Curtis JR; Landewé RB; Schiff MH; Khanna D; Kvien TK; Ionescu L; Gervitz LM; Davies OR; Luijtens K; Furst DE
    J Rheumatol; 2012 Jul; 39(7):1326-33. PubMed ID: 22589265
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.
    Curtis JR; Chen L; Luijtens K; Navarro-Millan I; Goel N; Gervitz L; Weinblatt M
    Arthritis Rheum; 2011 Aug; 63(8):2203-8. PubMed ID: 21484766
    [TBL] [Abstract][Full Text] [Related]  

  • 44. RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.
    Ramiro S; van Tubergen AM; Landewé RB
    Expert Rev Clin Immunol; 2010 Sep; 6(5):713-20. PubMed ID: 20828279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
    Genovese MC; Han C; Keystone EC; Hsia EC; Buchanan J; Gathany T; Murphy FT; Wu Z; Parasuraman S; Rahman MU
    J Rheumatol; 2012 Jun; 39(6):1185-91. PubMed ID: 22505702
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
    Feagan BG; Reilly MC; Gerlier L; Brabant Y; Brown M; Schreiber S
    Aliment Pharmacol Ther; 2010 Jun; 31(12):1276-85. PubMed ID: 20298497
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
    Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
    Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity.
    Strand V; Singh JA
    Drugs; 2010; 70(2):121-45. PubMed ID: 20108988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase.
    Schiff MH; von Kempis J; Goldblum R; Tesser JR; Mueller RB
    Ann Rheum Dis; 2014 Dec; 73(12):2174-7. PubMed ID: 24972708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year.
    Curtis JR; Luijtens K; Kavanaugh A
    Arthritis Care Res (Hoboken); 2012 May; 64(5):658-67. PubMed ID: 22231904
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study.
    Bi L; Li Y; He L; Xu H; Jiang Z; Wang Y; Li X; Wei W; Gu J; Wang G; Zhang Z; Zhou B; Liu Y; Wu Z; Liu H; He D; Lv Z; Li Z; Zuo X; Dong L; Wu H; Zhang H; Chen H; Bao C; Zhang Z; Zhang M; Song H; Zheng Y; Jiang L; Liu X; Boehnlein M; Dunkel J; Shao J; Harris K; Li Z
    Clin Exp Rheumatol; 2019; 37(2):227-234. PubMed ID: 30183595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
    Bingham CO; Weinblatt M; Han C; Gathany TA; Kim L; Lo KH; Baker D; Mendelsohn A; Westhovens R
    J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies.
    Takeuchi T; Yamamoto K; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2015 Jan; 25(1):11-20. PubMed ID: 24842476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study.
    Sarzi-Puttini P; Filippucci E; Adami S; Meroni PL; Batticciotto A; Idolazzi L; De Lucia O; Talavera P; Kumke T; Grassi W
    Adv Ther; 2018 Aug; 35(8):1153-1168. PubMed ID: 30043210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis.
    Kang YM; Park YE; Park W; Choe JY; Cho CS; Shim SC; Bae SC; Suh CH; Cha HS; Koh EM; Song YW; Yoo B; Lee SS; Park MC; Lee SH; Arendt C; Koetse W; Lee SK
    Korean J Intern Med; 2018 Nov; 33(6):1224-1233. PubMed ID: 29294598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cigarette smoking and clinical response to certolizumab pegol treatment in Hungarian, Czech, and Slovak patients with rheumatoid arthritis: 104-week data from the CIMDORA prospective, non-interventional study.
    Szekanecz Z; Koncz Á; Dunkel J; Vencovský J;
    Clin Exp Rheumatol; 2019; 37(6):1010-1018. PubMed ID: 30963993
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
    Tanaka Y; Takeuchi T; Izutsu H; Kaneko Y; Kato D; Fukuda M; Rokuda M; Schultz NM
    Arthritis Res Ther; 2021 Aug; 23(1):221. PubMed ID: 34429152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study.
    Strand V; Burmester GR; Ogale S; Devenport J; John A; Emery P
    Rheumatology (Oxford); 2012 Oct; 51(10):1860-9. PubMed ID: 22753773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.